Shots:

• This approval is based on data from DURATION-NEO-1 enrolling 375 patients for duration of 28 wks and DURATION-NEO-2- showing its safety and efficacy
•  The study involves evaluation of Bydureon BCise IV qw- showing (reduction in HbA1c with 1.4% vs. 1.0% for Byetta BID IV for 28 wks.); (reduction in mean wt. 1.5 Kg vs. 1.9 Kg (baseline-97 Kg) in combination with oral antidiabetic medicines)
• This new Bydureon BCise 2mg formulation qw has also received FDA approval in Oct 2017

 Ref: AstraZeneca | Image: AstraZeneca